Ближайший уровень поддержки по SPY – 195.00 уровень сопротивления – 196.00
LRCX продажа от 75
WLP покупка от 119
DWRE продажа ниже 58
Gapping up/down: SIMO +15% and CAMP +7% after earnings, FEYE +6% after new partnerships; GMCR +2% on upgrade at GS; SODA and TCS -15% after earnings/guidance; LVS -3% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: SIMO +14.9%, CAMP +7.2%, ISCA +4.9%, NLNK +1.9%, IDT +0.6%
Select Ebola related names showing strength: CMRX +3.9%, TKMR +3.4%, LAKE +2.8%
Select metals/mining stocks trading higher: IGLD +2.5%, IAG +0.8%, CDE +0.8%, SVM +0.6%
Other news: GTAT +15% (modest retracement following yesterday's massive decline), MAGS +15% (receives $8.2 mln of new orders; majority of the contracts are for expansions, changes and upgrades of existing homeland security installations in Israel), XCO +10.6% (announces sale of interests in Compass Production Partners), BCLI +9% (FDA grants fast track designation to NurOwn for the treatment of ALS), OXGN +8.3% (announced that data from the Phase 2 GOG186I study of fosbretabulin in combination with bevacizumab will be presented on November 9 at the International Gynecologic Cancer Society), GSAT +7.1% (issues statement in response to Kerrisdale Capital presentation), FEYE +5.8% (FireEye and SingTel partner to launch first managed defense solution; also, announced targeted attack protection for the Apple (AAPL) platform), BCRX +2.4% (announces late breaker presentation of OPuS-1 Phase 2 Trial results at the 23rd EADV Congress will be present Oct 11), ADHD +2.3% (after yesterday's 57% decline), ACHN +1.8% (disclosed it entered into a Master Security Agreement for a $1,000,000 Capital Expenditure Line of Credit), SBLK +1.6% (collected $8.016 mln from the sale of its claim against PAN OCEAN), REGN +1.3% (EYLEA (aflibercept) Injection received FDA approval for macular edema following retinal vein occlusion), PSTI +1.3% (wins cell therapy patent case in Europe; European Patent Office confirms validity of amended claims )
(
Читать дальше )